TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9401808

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Metronidazole‐gentamicin
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 122
Study: 8353699

Group type: EXPERIMENTAL
Intervention: Experimental group (community-based psychiatric services)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (hospital-based care)
Number of subjects: 172
Study: 30160584

Group type: EXPERIMENTAL
Intervention: Tai Chi classes for 3 or 4 weeks
Number of subjects: 10
Study: 28741390

Group type: EXPERIMENTAL
Intervention: Low maternal haemoglobin level (<130 g/L) in the first trimester
Number of subjects: 10430

Group type: EXPERIMENTAL
Intervention: High maternal haemoglobin level (≥130 g/L) in the second trimester
Number of subjects: 10430

Group type: COMPARATOR
Intervention: Normal maternal haemoglobin levels in both trimesters
Number of subjects: 10430
Study: 26429408

Group type: EXPERIMENTAL
Intervention: Locked Less Invasive Stabilization System (LISS; Synthes, Paoli, PA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 52
Study: 25179587

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg, twice daily, added to contingency management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (PBO), matched to NAC, added to contingency management
Number of subjects: 300
Study: 21939972

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT) for 5 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (conventional positioning)
Number of subjects: 27
Study: 20713903

Group type: EXPERIMENTAL
Intervention: Radial artery (RA) grafts
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saphenous vein (SV) grafts
Number of subjects: 27
Study: 18312071

Group type: EXPERIMENTAL
Intervention: Acidic fibroblast growth factor (FGF) applied during nerve repair surgery
Number of subjects: 9
Study: 16263986

Group type: EXPERIMENTAL
Intervention: Low-allergen maternal diet (excluded cow's milk, eggs, peanuts, tree nuts, wheat, soy, and fish)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (continued to consume allergenic foods)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-allergen maternal diet
Number of subjects: 90
Study: 12927761

Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.005% tropicamide
Number of subjects: 17
Study: 10552287

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8813487

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study: 1642945

Group type: EXPERIMENTAL
Intervention: esmolol hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 30
Study: 6666215

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (50‐200 micrograms/kg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous frusemide (1 mg/kg)
Number of subjects: 28
Study: 31615840

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 30223252

Group type: EXPERIMENTAL
Intervention: Aptima HPV (AHPV)
Number of subjects: 3475

Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 3475

Group type: EXPERIMENTAL
Intervention: AHPV
Number of subjects: 3475

Group type: COMPARATOR
Intervention: HC2
Number of subjects: 3475

Group type: EXPERIMENTAL
Intervention: AHPV- women
Number of subjects: 3475

Group type: COMPARATOR
Intervention: HC2- women
Number of subjects: 3475
Study: 26985851

Group type: EXPERIMENTAL
Intervention: IHW‐S (Indigenous health worker supported)
Number of subjects: 193

Group type: COMPARATOR
Intervention: UC (Usual care)
Number of subjects: 193
Study: 24139147

Group type: EXPERIMENTAL
Intervention: Left cathodal/right anodal transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study: 22554721

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg the night before surgery)
Number of subjects: 390
Study: 19781622

Group type: EXPERIMENTAL
Intervention: Maca extract (ME)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17633371

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI), 250 mL via intravenous dripping starting from 5 days before operation and after ending CPB once a day.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study: 14715085

Group type: EXPERIMENTAL
Intervention: Newly diagnosed cancer
Number of subjects: 504
Study: 11641659

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pregnancy (any trimester)
Number of subjects: 10
Study: 9870832

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg orally daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amphotericin B 0.5 mg/kg/day
Number of subjects: 106
Study: 8205374

Group type: EXPERIMENTAL
Intervention: Flogan (potassium diclofenac suspension)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cataflam (potassium diclofenac suspension)
Number of subjects: 18
Study: 2488496

Group type: EXPERIMENTAL
Intervention: Oral vitamin D 4,000 IU per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of ergocalciferol 600,000 IU every six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium intake of at least 1 g per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral ergocalciferol
Number of subjects: 0
Study: 1096276

Group type: EXPERIMENTAL
Intervention: Prenazone 600 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 20
Study: 31286828

Group type: EXPERIMENTAL
Intervention: Combined (active rTMS + fluoxetine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (sham rTMS + placebo fluoxetine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fluoxetine (sham rTMS + fluoxetine)
Number of subjects: 27
Study: 28455259

Group type: EXPERIMENTAL
Intervention: Manipulated Normative group
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Individualized Normative group
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 251
Study: 25653511

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg monotherapy
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg + antihypertensive combination therapy
Number of subjects: 335
Study: 23169790

Group type: EXPERIMENTAL
Intervention: Combined digital mammography and breast tomosynthesis
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Digital mammography alone
Number of subjects: 1192
Study: 21046285

Group type: EXPERIMENTAL
Intervention: AMG 114 (15 μg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AMG 114 (50 μg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AMG 114 (200 μg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 19298680

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 30
Study: 16505651

Group type: EXPERIMENTAL
Intervention: Rifampicin-minocycline (RM) coated catheters
Number of subjects: 646

Group type: COMPARATOR
Intervention: Silver-platinum-carbon (SPC) impregnated catheters
Number of subjects: 646
Study: 14567807

Group type: EXPERIMENTAL
Intervention: SprayGel adhesion barrier
Number of subjects: 14
Study: 10928668

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 81
Study: 8641482

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cauterization
Number of subjects: 17

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) and oral contraceptive (OC) therapy
Number of subjects: 17
Study: 1434782

Group type: EXPERIMENTAL
Intervention: High-pressure PEP-mask physiotherapy (PEP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PEP followed by AD (PEP-AD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AD followed by PEP (AD-PEP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No PT except for spontaneous coughing
Number of subjects: 14
Study: 3902531

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 75
Study: 31096945

Group type: EXPERIMENTAL
Intervention: OMNIgene®•SPUTUM (OM-S) medium
Number of subjects: 362

Group type: COMPARATOR
Intervention: Standard-of-care (SOC; cold-chain transported samples)
Number of subjects: 362
Study: 29384450

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral striatal area
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 10

Group type: COMPARATOR
Intervention: DBS OFF
Number of subjects: 10
Study: 28077163

Group type: EXPERIMENTAL
Intervention: Varenicline and behavioral support
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo and behavioral support
Number of subjects: 510
Study: 27530008

Group type: EXPERIMENTAL
Intervention: Modified Harvard's step test (VO₂max)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (VO₂max)
Number of subjects: 300
Study: 23219537

Group type: EXPERIMENTAL
Intervention: 100 mg avanafil
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 200 mg avanafil
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 20447774

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (62 Gy in 20 fractions within 5 weeks, 4 fractions/wk)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (80 Gy in 40 fractions within 8 weeks)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 168
Study: 19081791

Group type: EXPERIMENTAL
Intervention: NVP+AZT+ddI (Group A)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: NVP+3TC+d4T (Group B)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: NVP+AZT+3TC (Group C)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: HCV‐Ab positive patients with CD4 count >250/ul
Number of subjects: 198
Study: 17007488

Group type: EXPERIMENTAL
Intervention: V.A.C. Therapy
Number of subjects: 0
Study: 15074447

Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'free' speed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'slow' speed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'fast' speed
Number of subjects: 30

Group type: COMPARATOR
Intervention: Swedish subjects (control group)
Number of subjects: 30
Study: 10977030

Group type: EXPERIMENTAL
Intervention: Inhaled insulin powder (87.2 U)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Subcutaneous insulin (10.2 U)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous insulin (5.5 U)
Number of subjects: 13
Study: 9058683

Group type: EXPERIMENTAL
Intervention: Beef (raw, medium, and well-cooked)
Number of subjects: 335

Group type: COMPARATOR
Intervention: DBPCFC (double-blind placebo-controlled food challenges)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: SDS-PAGE analysis of beef extracts
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: IgE binding analysis
Number of subjects: 335
Study: 8485067

Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg bid
Number of subjects: 20
Study: 3959099

Group type: EXPERIMENTAL
Intervention: Retrospective measurement
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ongoing daily self-monitoring
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cognitive-affective changes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Behavioral changes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Therapeutic gains at follow-up
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Female partners
Number of subjects: 23
Study: 28654629

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (retreatment criteria not met)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab
Number of subjects: 0
Study: 27450670

Group type: EXPERIMENTAL
Intervention: Combined LL and OS restoration within 5mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gait symmetry
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinical scores
Number of subjects: 60
Study: 24311644

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1125 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 294 mg
Number of subjects: 52
Study: 23072834

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg/day for first 3 days, then 1 mg/day for 4 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21958943

Group type: EXPERIMENTAL
Intervention: E2/NETA (estradiol 2 mg/norethisterone acetate 1 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: COMPARATOR
Intervention: Black cohosh
Number of subjects: 154
Study: 18434919

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for pediatric major depressive disorder
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms at baseline
Number of subjects: 146
Study: 16254428

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 202
Study: 14605511

Group type: EXPERIMENTAL
Intervention: Niacin extended release/lovastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study: 10717926

Group type: EXPERIMENTAL
Intervention: Vobenzim (initial dose 18‐24 dragees, maintenance 12‐15 dragees a day)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pathogenetic therapy only (Control)
Number of subjects: 174
Study: 9175023

Group type: EXPERIMENTAL
Intervention: CD29 density on CD8+ cells
Number of subjects: 28
Study: 8263606

Group type: EXPERIMENTAL
Intervention: High fiber diet (31.3 g fiber/d, 586 mg calcium/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low fiber diet (6.5 g fiber/d, 530 mg calcium/d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High fiber diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 7
Study: 3744131

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (5,000 antifactor Xa U/24 h)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Low-dose conventional heparin (5,000 IU/12 h)
Number of subjects: 432
Study: 29966193

Group type: EXPERIMENTAL
Intervention: Personalized music playlists based on personal preferences
Number of subjects: 99
Study: 27255275

Group type: EXPERIMENTAL
Intervention: Peru (post-ratification of FTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peru (pre/post enforcement of FTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolivia (control)
Number of subjects: 0
Study: 24121658

Group type: EXPERIMENTAL
Intervention: G.O.A.L. intervention (90-min after-school physical activity club 4 days/week and one motivational interviewing session with a registered nurse)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G.O.A.L. intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Motivational interviewing session with a registered nurse
Number of subjects: 30
Study: 22329471

Group type: EXPERIMENTAL
Intervention: ARI + LTG
Number of subjects: 351

Group type: COMPARATOR
Intervention: PBO + LTG
Number of subjects: 351
Study: 20142219

Group type: EXPERIMENTAL
Intervention: Misago nitinol stent implantation
Number of subjects: 55
Study: 17943490

Group type: EXPERIMENTAL
Intervention: 12-week heavy resistance strength-training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neural approach (as a comparison)
Number of subjects: 0
Study: 20397590

Group type: EXPERIMENTAL
Intervention: Counter-stereotypic images (female scientists)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stereotypic images (male scientists)
Number of subjects: 100
Study: 15723201

Group type: EXPERIMENTAL
Intervention: Topical application of 100% tea tree oil (TTO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of 5% TTO lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of placebo lotion (no TTO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of 100% macadamia oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of 100% TTO
Number of subjects: 0
Study: 11772797

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg midazolam syrup
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam syrup
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam syrup
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam syrup (maximum 20 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All doses of midazolam syrup
Number of subjects: 95
Study: 9674809

Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone high dose
Number of subjects: 108

Group type: COMPARATOR
Intervention: i.v. methylprednisolone low dose
Number of subjects: 108
Study: 7988623

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg + 250 mg) + Midazolam 10 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Erythromycin 750 mg (as a positive control)
Number of subjects: 64
Study: 3052965

Group type: EXPERIMENTAL
Intervention: naproxen 10 mg/kg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: tolmetin 25 mg/kg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: diclofenac 2 mg/kg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 28

Group type: COMPARATOR
Intervention: tolmetin
Number of subjects: 28

Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 28
Study: 31376878

Group type: EXPERIMENTAL
Intervention: Placebo preconditioning in the morning (08:00-10:00) with high endogenous cortisol levels
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo preconditioning in the afternoon (16:00-18:00) with low endogenous cortisol levels
Number of subjects: 77
Study: 30384842

Group type: EXPERIMENTAL
Intervention: iv exenatide (1‐h bolus of 0.05 µg min‐1 followed by a constant infusion of 0.025 µg min‐1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: iv exenatide
Number of subjects: 92

Group type: COMPARATOR
Intervention: iv insulin therapy (control group)
Number of subjects: 92
Study: 27368117

Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 109

Group type: COMPARATOR
Intervention: EU trastuzumab
Number of subjects: 109

Group type: COMPARATOR
Intervention: US trastuzumab
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: SB3, EU trastuzumab, US trastuzumab
Number of subjects: 109
Study: 24274806

Group type: EXPERIMENTAL
Intervention: Tailored interventions (specific details on dosage and duration not provided)
Number of subjects: 9077

Group type: COMPARATOR
Intervention: Control condition (specific details not provided)
Number of subjects: 9077

Group type: EXPERIMENTAL
Intervention: Tailored interventions
Number of subjects: 9077
Study: 21673137

Group type: EXPERIMENTAL
Intervention: Pasireotide 450 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide 900 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide 1350 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide 1800 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide 2250 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide 2025 µg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pasireotide infusion
Number of subjects: 44
Study: 21165861

Group type: EXPERIMENTAL
Intervention: Hazard nature image category
Number of subjects: 109

Group type: COMPARATOR
Intervention: Other image categories (prospect, refuge, mixed prospect and refuge)
Number of subjects: 109
Study: 17497983

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Scissors for dissection and ligatures for haemostasis
Number of subjects: 160

Group type: COMPARATOR
Intervention: Suction drain
Number of subjects: 160

Group type: COMPARATOR
Intervention: Corrugated drains
Number of subjects: 160
Study: 16113179

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as a slow intravenous infusion over 15 minutes (SIG group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 10 mg metoclopramide intravenous bolus infusion over two minutes (BIG group)
Number of subjects: 300
Study: 12107041

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Acamprosate plus minimal intervention (3‐weekly sessions of 20 min)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Acamprosate plus brief cognitive behavioural therapy (7‐weekly sessions of 60 min)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (Acamprosate only)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 248
Study: 10414418

Group type: EXPERIMENTAL
Intervention: Toluene diisocyanate (TDI) exposure (5 ppb for 6 h followed by 20 ppb for 20 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Toluene diisocyanate (TDI) exposure
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 17